- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02274415
Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease (DREVAC)
Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti-pneumococcal and Polysaccharide Anti-pneumococcal Vaccine Compared to Polysaccharide Anti -Pneumococcal Vaccine Alone in Patients With Sickle Cells Disease
Streptococcus pneumoniae is the major cause of bacterial infection in patients with sickle cells disease.
The 23-valent pneumococcal polysaccharide vaccine (PSV) is supposed to be poorly immunogenic in these patients. We want to evaluate whether a prime with a 13-valent pneumococcal conjugate vaccine (PCV), able to induce immunologic memory, would improve the immune response against SP polysaccharides (SPP).
Primary objective: To evaluate and compare the specific antibody response to a prime-boost vaccine strategy combining PCV prime at W0 followed by the administration of PSV boost at W4, to the administration of PSV alone at W4 in patients with sickle cells disease.
Secondary objectives: Evaluation and comparison of the specific antibody response to the thirteen pneumococcal serotypes shared by the PCV and PSV vaccines, 4 weeks after the single PSV vaccination for patients from Group 1 or 4 weeks after the boost PSV vaccination for patients from group 2. Evaluation of the duration of the specific antibody response at W24 and 96. Evaluation of the T CD4 lymphocyte response to the CRM 197 protein. Safety of the vaccines.
Study Design: Randomised, monocentric, controlled phase II study of the immunological efficacy of a prime boost strategy combining the sequential administration of the PCV and PSV, compared to the administration of the PSV alone. 180 adults patients with sickle cells disease will be included. The primary endpoint : proportion of responders at W8 to at least 10 of thirteen serotypes. Secondary endpoints : Proportion of responders at W8 according to 4 categories of responders: 5-7; 3-4; 2-1 and 0. Evaluation of the pneumococcal opsonophagocytic activity (OPA) at baseline and W8 for each serotype, defined as the proportion of patients with OPA > 1:8 geometric mean of the specific antibody titers proportion of patients who experienced an increase of specific antibody levels 1 g/ml. Evaluation of the priming effect of the PCV vaccine in the group 1. Duration of the specific antibody responses at week 24 and W96. CD4 T lymphocyte responses to the CRM 197 protein (proliferative and cytokine production) at weeks 0, 8 and 12. Safety of the vaccines frequency of Streptococcus pneumoniae infections.
Statistical Considerations: With a sample size of 180 patients, and a randomization ration of 1:1, the study will have a power of at least 90% to show a difference of 25% category between the group receiving PCV and PSV vs the group receiving PSV alone (two-sided type I error = 5%). The primary comparison between both groups will be performed using a Chi2 test for independent groups or a Fisher exact test where appropriate.
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Creteil, France, 94010
- Henri Mondor Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Adult patient with sickle cell anemia (SS homozygous, SC heterozygous compound Sbetathal heterozygous)
Exclusion Criteria:
- Heterozygous sickle cell anemia
- Active infection
- Hypersensitivity known or suspected to Prevenar 13® or to Pneumo 23® or to any of the excipients included in the formulation or in the administration system
- Coagulation abnormality indicating against an intramuscular injection (Platelets <50 000 or TP<50%)
- Current chemotherapy or radiotherapy, except for using Siklos®/Hydrea® in the context of sickle cell anemia
- Vaccination whatever in the last 2 months before the protocol vaccination, except influenza vaccination (within 30 days)
- Vaccination whatever, provided in the first 2 months following the protocol vaccinations, except influenza vaccination (within the first month following the protocol vaccinations))
- History of pneumococcal vaccination with Pneumo 23® in the previous year
- End-stage renal failure(dialyzed patient, clearance<10ml/mn)
- HIV infection at baseline
- Pregnancy or breastfeeding (A dosage of betaHCG will be conducted for women in childbearing age),contraception recommendation the first 8 weeks of the test for women in childbearing age
- Participation in a clinical research protocol using a drug within the month prior to inclusion.
- No medical assurance
- Adults under tutelage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PCV vaccine following by the PSV vaccine
Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
|
|
ACTIVE_COMPARATOR: vaccine Pneumo 23
Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of responders at least to 10 of thirteen serotypes
Time Frame: at Week 8
|
A responder is defined by a rise least two fold from baseline) of antibody titers specific to pneumococcal serotypes;
|
at Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of responders according to 4 categories of responders: 5-7; 3-4; 2-1 and 0.
Time Frame: at Week 8
|
Response is defined as fold rise of antibody titers (W8 to baseline)
|
at Week 8
|
Evaluation of the pneumococcal opsonophagocytic activity (OPA) for each serotype,
Time Frame: at baseline and Week 8
|
defined as the proportion of patients with OPA > 1:8.
|
at baseline and Week 8
|
The antibody response of the conjugate vaccine
Time Frame: at week 4
|
The antibody response to the 13 serotypes of the conjugate vaccine in terms of geometric mean of the specific antibody titers (µg/ml)
|
at week 4
|
The antibody response to the 13 serotypes of the conjugate vaccine in terms of proportion of patients
Time Frame: at week 4
|
at week 4
|
|
In the group 1 antibodies titers (µg/ml)
Time Frame: at week 24 and W96
|
at week 24 and W96
|
|
Number of T CD4 cells responsive to the CRM 197 protein (proliferative and cytokine production) in the two groups of the study
Time Frame: at weeks 0, 8 and 12.
|
at weeks 0, 8 and 12.
|
|
Number of Streptococcus pneumoniae infections
Time Frame: between baseline and W96
|
Number of Streptococcus pneumoniae infections (bacteremia, meningitis, pneumonia, sinusitis, upper respiratory tract infections)
|
between baseline and W96
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yves LEVY, PHD, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Hematologic Diseases
- Genetic Diseases, Inborn
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Pneumococcal Infections
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- AOM10028
- P100105 (OTHER: Assistance Publique Hôpitaux de Paris)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cells Disease
-
Società Italiana Talassemie ed EmoglobinopatieCompleted
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI); New York Blood CenterRecruiting
-
MiCareo Taiwan Co., Ltd.Unknown
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingSickle Cell Disease | Sickle Cell SC Disease | Sickle Cell-SS Disease | Sickle Cell RetinopathyNetherlands
-
UNC Lineberger Comprehensive Cancer CenterCompletedCirculating Tumor CellsUnited States
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
Clinical Trials on Vaccination with the combined vaccine (Prevenar13 ®)
-
Chinese University of Hong KongThe University of Hong Kong; Health and Medical Research FundRecruitingQuality of Life | Covid19 | Exercise Capacity | Lung FunctionHong Kong
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
-
Sinovac Biotech Co., LtdCompletedInfluenza and PneumoniaChina
-
Sinovac Research and Development Co., Ltd.Completed
-
University Hospital, GenevaRecruitingLiver Disease | Varicella | ImmunosuppressionSwitzerland
-
St George's, University of LondonMax Planck Institute for Infection Biology; Innovative Medicine InitiativeCompletedPregnancy Related | VaccinationUnited Kingdom
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingMonkey Pox | Monkey DiseasesFrance
-
Johns Hopkins UniversityMerck Sharp & Dohme LLCCompletedChronic Kidney DiseaseUnited States
-
University of OxfordCompletedType 1 Diabetes MellitusUnited Kingdom